Properties (65)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Gaithersburg_facility
|
| gptkbp:ADC |
Matrix-M adjuvant
|
| gptkbp:approves |
stringent regulatory review
|
| gptkbp:CEO |
gptkb:Stanley_C._Erck
|
| gptkbp:clinicalTrials |
over 30,000
multiple sites Phase 3 trials for COVID-19 vaccine Phase 2/3 |
| gptkbp:collaborations |
gptkb:University_of_Maryland
gptkb:University_of_Queensland gptkb:Institute_of_Health_Research academic institutions international research teams |
| gptkbp:community_engagement |
public health initiatives
|
| gptkbp:community_involvement |
local health organizations
|
| gptkbp:community_outreach |
public awareness campaigns
|
| gptkbp:coolingSystem |
refrigerated
|
| gptkbp:diseaseResistance |
two doses
reduced disease transmission over 90% in trials |
| gptkbp:distribution |
various governments
|
| gptkbp:dosageForm |
two
|
| gptkbp:economy |
economic recovery efforts
|
| gptkbp:education |
healthcare_professionals
|
| gptkbp:educational_programs |
informational resources
|
| gptkbp:focus |
vaccine development
|
| gptkbp:founded |
1987
|
| gptkbp:founder |
gptkb:Stanley_C._Erck
|
| gptkbp:funding |
government grants
U.S._government_funding |
| gptkbp:geographicalFeature |
multiple countries
|
| gptkbp:headquarters |
gptkb:Gaithersburg,_Maryland
|
| gptkbp:healthcare |
improved vaccination rates
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novavax
|
| gptkbp:impact |
global pandemic response
protein subunit vaccine |
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:innovation |
new methodologies
advanced research |
| gptkbp:investmentFocus |
private sector funding
significant funding |
| gptkbp:network |
global supply chain
|
| gptkbp:notable_player |
gptkb:COVAX_initiative
2-8 degrees Celsius WHO Emergency Use Listing recombinant nanoparticle technology |
| gptkbp:notableEvent |
gptkb:NVX-CoV2373
|
| gptkbp:partnerships |
gptkb:CEPI
gptkb:Gavi,_the_Vaccine_Alliance various global health organizations |
| gptkbp:produces |
scalable manufacturing
|
| gptkbp:regulatoryCompliance |
Emergency Use Authorization
|
| gptkbp:research |
ongoing
|
| gptkbp:safety |
monitored in trials
|
| gptkbp:safetyFeatures |
post-marketing surveillance
|
| gptkbp:scientificName |
gptkb:Nuvaxovid
|
| gptkbp:shoots |
against variants
|
| gptkbp:status |
under review
|
| gptkbp:stockExchange |
NASDAQ:_NVAX
|
| gptkbp:targets |
SARS-CoV-2
|
| gptkbp:technology |
rapid response capabilities
innovative approaches cutting-edge science |
| gptkbp:triggerType |
subunit vaccine
|